cytosine has been researched along with Alastrim in 37 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most common adverse events were mild gastrointestinal events and asymptomatic, transient, and reversible elevations in serum transaminases." | 2.84 | Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. ( Brundage, T; Chittick, G; Morrison, M; Nichols, WG, 2017) |
| "Although smallpox has been eliminated from the environment, treatments are urgently being sought due to the risk of smallpox being used as a bioterrorism agent and for monkeypox virus, a zoonotic disease of Africa, and adverse reactions to smallpox virus vaccinations." | 2.47 | Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. ( Adams, MM; Foster, S; Lampert, B; Moyer, RW; Painter, G; Rice, AD; Robertson, A, 2011) |
| " Here we extend these studies by exploring different dosing regimens and performing randomized, blinded, placebo-controlled studies." | 2.47 | Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. ( Adams, MM; Burrage, AM; Foster, S; Gray, SA; Lampert, B; Lanier, R; Lindsey, SF; Manning, BR; Moyer, RW; Painter, G; Rice, AD; Robertson, A; Smith, AJ; Swetnam, D; Wallace, G, 2011) |
| "Smallpox is spread by human-to-human contact with an infected host and therefore can be contagious." | 2.42 | Smallpox: clinical features, prevention, and management. ( Blair, DC; Guharoy, R; Krenzelok, EP; Noviasky, JA; Panzik, R, 2004) |
| "Smallpox is one of the deadliest infectious diseases in history." | 1.31 | The smallpox vaccine and postvaccinal encephalitis. ( Eckerman, NL; Roos, KL, 2002) |
| "Smallpox is a disease that followed humanity for thousands of years up until 30 years ago." | 1.31 | Smallpox--eradicated, but a growing terror threat. ( Elgh, F; Tegnell, A; Wahren, B, 2002) |
| "The efficacy of cidofovir for treatment of cowpox virus infection in BALB/c mice was investigated in an effort to evaluate new therapies for virulent orthopoxvirus infections of the respiratory tract in a small animal model." | 1.31 | Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. ( Bray, M; Huggins, JW; Kefauver, D; Martinez, M; Smee, DF; Thompson, E, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (51.35) | 29.6817 |
| 2010's | 14 (37.84) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Parker, S | 4 |
| D'Angelo, J | 1 |
| Buller, RM | 2 |
| Smee, DF | 3 |
| Lantto, J | 1 |
| Nielsen, H | 1 |
| Jensen, A | 1 |
| Prichard, M | 1 |
| George, SL | 1 |
| Chan-Tack, K | 1 |
| Harrington, P | 1 |
| Bensman, T | 1 |
| Choi, SY | 1 |
| Donaldson, E | 1 |
| O'Rear, J | 1 |
| McMillan, D | 1 |
| Myers, L | 1 |
| Seaton, M | 1 |
| Ghantous, H | 1 |
| Cao, Y | 1 |
| Valappil, T | 1 |
| Birnkrant, D | 1 |
| Struble, K | 1 |
| Huston, J | 1 |
| Curtis, S | 1 |
| Egelund, EF | 1 |
| Delaune, D | 1 |
| Iseni, F | 1 |
| Grossi, IM | 1 |
| Foster, SA | 3 |
| Gainey, MR | 1 |
| Krile, RT | 1 |
| Dunn, JA | 1 |
| Brundage, T | 2 |
| Khouri, JM | 1 |
| Lanier, R | 3 |
| Olson, VA | 2 |
| Smith, SK | 1 |
| Foster, S | 4 |
| Li, Y | 1 |
| Lanier, ER | 1 |
| Gates, I | 1 |
| Trost, LC | 2 |
| Damon, IK | 2 |
| Guimarães, AP | 1 |
| de Souza, FR | 1 |
| Oliveira, AA | 1 |
| Gonçalves, AS | 1 |
| de Alencastro, RB | 1 |
| Ramalho, TC | 1 |
| França, TC | 1 |
| Rose, ML | 1 |
| Khouri, J | 1 |
| Keilholz, L | 1 |
| Long, J | 1 |
| Godin, SJ | 1 |
| Crump, R | 1 |
| Korom, M | 1 |
| Chittick, G | 1 |
| Morrison, M | 1 |
| Nichols, WG | 1 |
| Rice, AD | 3 |
| Adams, MM | 3 |
| Lampert, B | 2 |
| Robertson, A | 2 |
| Painter, G | 3 |
| Moyer, RW | 3 |
| Wallace, G | 1 |
| Burrage, AM | 1 |
| Lindsey, SF | 1 |
| Smith, AJ | 1 |
| Swetnam, D | 1 |
| Manning, BR | 1 |
| Gray, SA | 1 |
| Hayden, EC | 1 |
| Vere Hodge, A | 1 |
| Chen, NG | 1 |
| Hartzler, H | 1 |
| Hembrador, E | 1 |
| Hruby, D | 1 |
| Jordan, R | 1 |
| Painter, W | 1 |
| Sagartz, JE | 1 |
| Schriewer, J | 1 |
| Mark Buller, R | 1 |
| Arndt, W | 1 |
| Mitnik, C | 1 |
| Denzler, KL | 1 |
| White, S | 1 |
| Waters, R | 1 |
| Jacobs, BL | 1 |
| Rochon, Y | 1 |
| Langland, JO | 1 |
| McConnell, J | 1 |
| Roos, KL | 1 |
| Eckerman, NL | 1 |
| Tegnell, A | 1 |
| Wahren, B | 1 |
| Elgh, F | 1 |
| Neyts, J | 1 |
| De Clercq, E | 1 |
| Sidwell, RW | 1 |
| Toro, JR | 1 |
| Sanchez, S | 1 |
| Turiansky, G | 1 |
| Blauvelt, A | 1 |
| Check, E | 2 |
| Guharoy, R | 1 |
| Panzik, R | 1 |
| Noviasky, JA | 1 |
| Krenzelok, EP | 1 |
| Blair, DC | 1 |
| Bray, M | 2 |
| Roy, CJ | 1 |
| Shinzato, T | 1 |
| Goff, A | 1 |
| Twenhafel, N | 1 |
| Garrison, A | 1 |
| Mucker, E | 1 |
| Lawler, J | 1 |
| Paragas, J | 1 |
| Martinez, M | 1 |
| Kefauver, D | 1 |
| Thompson, E | 1 |
| Huggins, JW | 1 |
| Cohen, J | 1 |
| Bradbury, J | 1 |
| Ridings, H | 1 |
| Evans, M | 1 |
| Morris, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| European Randomised Clinical Trial on mPOX Infection[NCT06156566] | Phase 4 | 150 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for cytosine and Alastrim
| Article | Year |
|---|---|
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation.
Topics: Animals; Antiviral Agents; Cytosine; Disease Eradication; Disease Models, Animal; Drug Approval; Hum | 2021 |
Brincidofovir: A Novel Agent for the Treatment of Smallpox.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytosine; Disease Models, Animal; Hematopoietic Stem Cel | 2023 |
Drug Development against Smallpox: Present and Future.
Topics: Animals; Antiviral Agents; Benzamides; Biological Warfare Agents; Biomedical Research; Cytosine; Dis | 2020 |
Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Topics: Animals; Antiviral Agents; Bioterrorism; Cytosine; Disease Models, Animal; Disease Transmission, Inf | 2011 |
Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Topics: Animals; Antiviral Agents; Cytosine; Disease Models, Animal; Disease Transmission, Infectious; Dose- | 2011 |
Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; History, 20th Century; Humans; Organophosphonates; O | 2003 |
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
Topics: Animals; Antiviral Agents; Bioterrorism; Cidofovir; Cytosine; Disease Models, Animal; Humans; Mice; | 2003 |
Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox.
Topics: Administration, Cutaneous; Administration, Topical; Antiviral Agents; Carcinoma in Situ; Carcinoma, | 2003 |
Smallpox: clinical features, prevention, and management.
Topics: Antiviral Agents; Bioterrorism; Cidofovir; Cytosine; Female; Humans; Infant; Male; Organophosphonate | 2004 |
Antiviral prophylaxis of smallpox.
Topics: Antiviral Agents; Cidofovir; Combined Modality Therapy; Cytosine; Humans; Organophosphonates; Organo | 2004 |
[Smallpox].
Topics: Animals; Antiviral Agents; Bioterrorism; Cidofovir; Cytosine; Diagnosis, Differential; Humans; Organ | 2004 |
Understanding the threat of smallpox.
Topics: Bioterrorism; Cidofovir; Cytosine; Diagnosis, Differential; Humans; Organophosphonates; Organophosph | 2002 |
1 trial available for cytosine and Alastrim
| Article | Year |
|---|---|
Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.
Topics: Adenoviridae; Adolescent; Adult; Animals; Antiviral Agents; Cytomegalovirus; Cytosine; Disease Model | 2017 |
24 other studies available for cytosine and Alastrim
| Article | Year |
|---|---|
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Topics: Animals; Antiviral Agents; Benzamides; Cell Line; Chlorocebus aethiops; Cytosine; Female; Humans; Im | 2021 |
Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Body Temperature; Body Weigh | 2017 |
The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak.
Topics: Animals; Antiviral Agents; Benzamides; Biological Warfare Agents; Cytosine; Databases, Pharmaceutica | 2017 |
The spectre of smallpox lingers.
Topics: Animals; Benzamides; Cytosine; Disease Eradication; Disease Models, Animal; Disease Reservoirs; Drug | 2018 |
In vitro efficacy of brincidofovir against variola virus.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cidofovir; Cytosine; Disease Models, Ani | 2014 |
Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox.
Topics: Acyclovir; Antiviral Agents; Catalytic Domain; Cidofovir; Cytosine; Drug Design; Humans; Kinetics; L | 2015 |
The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Cidofovir; Cytosine; Disease | 2015 |
Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Topics: Animals; Antiviral Agents; Cytosine; Disease Models, Animal; DNA, Viral; Ectromelia virus; Ectromeli | 2017 |
Biodefence since 9/11: The price of protection.
Topics: Animals; Antiviral Agents; Biomedical Research; Bioterrorism; Budgets; Cytosine; Disease Models, Ani | 2011 |
Scientific report: highlights of 24th ICAR, 8-11 May 2011, Sofia, Bulgaria.
Topics: Adenine; Animals; Antiviral Agents; Arenavirus; Chemistry, Pharmaceutical; Communicable Diseases, Em | 2011 |
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Topics: Animals; Benzamides; Biomarkers, Pharmacological; Cell Line; Cytosine; Disease Models, Animal; Drug | 2012 |
In vitro characterization of a nineteenth-century therapy for smallpox.
Topics: Animals; Canada; Cell Line; Cidofovir; Cytosine; Fluorescent Antibody Technique; HeLa Cells; History | 2012 |
Gearing up for smallpox.
Topics: Animals; Antiviral Agents; Bioterrorism; Cidofovir; Cytosine; Humans; Macaca fascicularis; Organopho | 2002 |
The smallpox vaccine and postvaccinal encephalitis.
Topics: Animals; Antibodies, Viral; Antiviral Agents; Bioterrorism; Cidofovir; Contraindications; Cytosine; | 2002 |
Smallpox--eradicated, but a growing terror threat.
Topics: Antiviral Agents; Biological Warfare; Bioterrorism; Cidofovir; Cytosine; Europe; History, 16th Centu | 2002 |
Boom, or bust?
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Animals; Bacterial Vaccines; Biomedical Re | 2003 |
Unanimous vote approves tweak to smallpox genome.
Topics: Cidofovir; Cytosine; Drug Evaluation, Preclinical; Genes, Reporter; Genetic Engineering; Genome, Vir | 2004 |
In vivo imaging of cidofovir treatment of cowpox virus infection.
Topics: Animals; Antiviral Agents; Bioterrorism; Chlorocebus aethiops; Cidofovir; Cowpox; Cowpox virus; Cyto | 2007 |
Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; Humans; Organophosphonates; | 2007 |
Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.
Topics: Administration, Intranasal; Aerosols; Animals; Antiviral Agents; Bronchi; Cidofovir; Cowpox; Cytosin | 2000 |
Bioterrorism. Blocking smallpox: a second defense.
Topics: Animals; Antiviral Agents; Bioterrorism; Cidofovir; Cytosine; Disease Models, Animal; Disease Outbre | 2001 |
Smallpox eradication: destruction of variola virus stocks.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; DNA, Viral; Humans; Macaca fascicularis; Mice; Model | 2002 |
Orally available cidofovir derivative active against smallpox.
Topics: Administration, Oral; Cidofovir; Cytosine; Humans; Organophosphonates; Organophosphorus Compounds; S | 2002 |
Oral drug and old vaccine renew smallpox bioterror debate.
Topics: Animals; Antiviral Agents; Bioterrorism; Cidofovir; Contraindications; Cytosine; Humans; Organophosp | 2002 |